Literature DB >> 16873282

CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.

C W Tsang1, X Lin, N H Gudgeon, G S Taylor, H Jia, E P Hui, A T C Chan, C K Lin, A B Rickinson.   

Abstract

Epstein-Barr virus nuclear antigen EBNA1, the one viral protein uniformly expressed in nasopharyngeal carcinoma (NPC), represents a prime target for T-cell-based immunotherapy. However, little is known about the EBNA1 epitopes, particularly CD4 epitopes, presented by HLA alleles in Chinese people, the group at highest risk for NPC. We analyzed the CD4+ T-cell responses to EBNA1 in 78 healthy Chinese donors and found marked focusing on a small number of epitopes in the EBNA1 C-terminal region, including a DP5-restricted epitope that was recognized by almost half of the donors tested and elicited responses able to recognize EBNA1-expressing, DP5-positive target cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873282      PMCID: PMC1563796          DOI: 10.1128/JVI.00400-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Requirement for CD4 T cell help in generating functional CD8 T cell memory.

Authors:  Devon J Shedlock; Hao Shen
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

2.  Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs.

Authors:  R Khanna; S R Burrows; S A Thomson; D J Moss; P Cresswell; L M Poulsen; L Cooper
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

3.  Expression of HLA-DR antigens in nasopharyngeal carcinoma: an immunohistological analysis of the tumour cells and infiltrating lymphocytes.

Authors:  J A Thomas; V Iliescu; D H Crawford; R Ellouz; M Cammoun; G de-Thé
Journal:  Int J Cancer       Date:  1984-06-15       Impact factor: 7.396

4.  Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.

Authors:  P Comoli; R De Palma; S Siena; A Nocera; S Basso; F Del Galdo; R Schiavo; O Carminati; A Tagliamacco; G F Abbate; F Locatelli; R Maccario; P Pedrazzoli
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

5.  Immunohistological characteristics of the infiltrating lymphoid cells and expression of HLA class I and II antigens in nasopharyngeal carcinoma.

Authors:  F M Lai; P N Cheng; S Y Tsao; K N Lai
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

6.  Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.

Authors:  G S Taylor; T A Haigh; N H Gudgeon; R J Phelps; S P Lee; N M Steven; A B Rickinson
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Authors:  Karin C M Straathof; Catherine M Bollard; Uday Popat; M Helen Huls; Teresita Lopez; M Craig Morriss; Mary V Gresik; Adrian P Gee; Heidi V Russell; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2004-11-12       Impact factor: 22.113

8.  CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.

Authors:  H M Long; T A Haigh; N H Gudgeon; A M Leen; C-W Tsang; J Brooks; E Landais; E Houssaint; S P Lee; A B Rickinson; G S Taylor
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Authors:  C Münz; K L Bickham; M Subklewe; M L Tsang; A Chahroudi; M G Kurilla; D Zhang; M O'Donnell; R M Steinman
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

10.  Defective CD8 T cell memory following acute infection without CD4 T cell help.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

View more
  9 in total

1.  Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Authors:  Edwin P Hui; Graham S Taylor; Hui Jia; Brigette B Y Ma; Stephen L Chan; Rosalie Ho; Wai-Lap Wong; Steven Wilson; Benjamin F Johnson; Ceri Edwards; Deborah D Stocken; Alan B Rickinson; Neil M Steven; Anthony T C Chan
Journal:  Cancer Res       Date:  2013-01-24       Impact factor: 12.701

2.  Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.

Authors:  Yong Zheng; Greg Parsonage; Xiaodong Zhuang; Lee R Machado; Christine H James; Asmaa Salman; Peter F Searle; Edwin P Hui; Anthony T C Chan; Steven P Lee
Journal:  Cancer Immunol Res       Date:  2015-02-24       Impact factor: 11.151

3.  Burkitt lymphoma: pathogenesis and immune evasion.

Authors:  Jason M God; Azizul Haque
Journal:  J Oncol       Date:  2010-10-05       Impact factor: 4.375

Review 4.  Nasopharyngeal carcinoma: molecular biomarker discovery and progress.

Authors:  William Chi-Shing Cho
Journal:  Mol Cancer       Date:  2007-01-02       Impact factor: 27.401

5.  Epstein-Barr virus genetic variation in lymphoblastoid cell lines derived from Kenyan pediatric population.

Authors:  Kenneth O Simbiri; Nicholas A Smith; Richard Otieno; Eric E M Wohlford; Ibrahim I Daud; Sumba P Odada; Frank Middleton; Rosemary Rochford
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 6.  Contribution of Epstein⁻Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma.

Authors:  Katerina Vrzalikova; Taofik Sunmonu; Gary Reynolds; Paul Murray
Journal:  Pathogens       Date:  2018-06-27

7.  A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Authors:  Graham S Taylor; Hui Jia; Kevin Harrington; Lip Wai Lee; James Turner; Kristin Ladell; David A Price; Manjit Tanday; Jen Matthews; Claudia Roberts; Ceri Edwards; Lesley McGuigan; Andrew Hartley; Steve Wilson; Edwin P Hui; Anthony T C Chan; Alan B Rickinson; Neil M Steven
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

8.  EBV-Associated Cancer and Autoimmunity: Searching for Therapies.

Authors:  Giovanni Capone; Candida Fasano; Guglielmo Lucchese; Michele Calabrò; Darja Kanduc
Journal:  Vaccines (Basel)       Date:  2015-02-05

9.  Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.

Authors:  Monika Tschochner; Shay Leary; Don Cooper; Kaija Strautins; Abha Chopra; Hayley Clark; Linda Choo; David Dunn; Ian James; William M Carroll; Allan G Kermode; David Nolan
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.